We are live on ! Find out more
AVBP icon

ArriVent BioPharma
AVBP

99 hedge funds and large institutions have $732M invested in ArriVent BioPharma in 2025 Q2 according to their latest regulatory filings, with 26 funds opening new positions, 25 increasing their positions, 30 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

189% more first-time investments, than exits

New positions opened: 26 | Existing positions closed: 9

36% more capital invested

Capital invested by funds: $539M → $732M (+$193M)

20% more funds holding in top 10

Funds holding in top 10: 5 → 6 (+1)

19% more funds holding

Funds holding: 83 → 99 (+16)

12.82% more ownership

Funds ownership: 85.46% → 98.29% (+13%)

17% less repeat investments, than reductions

Existing positions increased: 25 | Existing positions reduced: 30

Holders
99
Holders Change
+16
Holders Change %
+19.28%
% of All Funds
1.3%
Holding in Top 10
6
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+20%
% of All Funds
0.08%
New
26
Increased
25
Reduced
30
Closed
9
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
IAM
Infinitum Asset Management
Florida
+$28.1M
2
SCM
Suvretta Capital Management
New York
+$22.3M
3
SL
Siren LLC
Connecticut
+$14.5M
4
F1I
Fund 1 Investments
Puerto Rico
+$11M
5
CLG
Cooperman Leon G
+$8.75M

Top Sellers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
-$6.26M
2
UBS Group
UBS Group
Switzerland
-$2.4M
3
OCA
Octagon Capital Advisors
New York
-$2.35M
4
Two Sigma Investments
Two Sigma Investments
New York
-$765K
5
Marshall Wace
Marshall Wace
United Kingdom
-$663K
Name Holding Trade Value Shares
Change 		Change in
Stake
US Bancorp
76
US Bancorp
Minnesota
$24.5K +$16.7K +805 +250%
AB
77
Amalgamated Bank
New York
$21K – – –
GFM
78
GF Fund Management
China
$18.8K – – –
Carson Wealth (CWM LLC)
79
Carson Wealth (CWM LLC)
Nebraska
$10K +$6.89K +332 +261%
Zurich Cantonal Bank
80
Zurich Cantonal Bank
Switzerland
$8.9K -$997 -48 -11%
VCM
81
Versant Capital Management
Arizona
$8.19K +$7.81K +376 New
Nisa Investment Advisors
82
Nisa Investment Advisors
Missouri
$7.27K +$6.38K +307 +1,137%
Osaic Holdings
83
Osaic Holdings
Arizona
$3.38K +$3.51K +169 New
AF
84
Allworth Financial
California
$2.68K +$1.95K +94 +324%
GI
85
GAMMA Investing
California
$2.15K -$955 -46 -32%
Daiwa Securities Group
86
Daiwa Securities Group
Japan
$2K – – –
PA
87
Parallel Advisors
California
$1.78K +$1.7K +82 New
SCM
88
Sterling Capital Management
North Carolina
$1.22K -$3.18K -153 -73%
Royal Bank of Canada
89
Royal Bank of Canada
Ontario, Canada
$1K -$2.49K -120 -83%
EWA
90
EverSource Wealth Advisors
Alabama
$805 +$768 +37 New
SS
91
SBI Securities
Japan
$544 – – –
Russell Investments Group
92
Russell Investments Group
United Kingdom
$457 +$436 +21 New
RIL
93
Rothschild Investment LLC
Illinois
$435 -$1.04K -50 -71%
S
94
SignatureFD
Georgia
$392 +$374 +18 New
PS
95
Principal Securities
Iowa
$348 +$332 +16 New
IA
96
IFP Advisors
Florida
$22 – – –
CA
97
Clearstead Advisors
Ohio
$22 +$21 +1 New
Two Sigma Investments
98
Two Sigma Investments
New York
– -$765K -41,381 Closed
Marshall Wace
99
Marshall Wace
United Kingdom
– -$663K -35,851 Closed
AA
100
ALPS Advisors
Colorado
– -$465K -25,167 Closed
1 2 3
4
5

AVBP Hedge Fund Activity: Q2 2025 in Review

99 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in ArriVent BioPharma (AVBP) for Q2 2025, worth a combined $732M — up 36% from $539M a quarter earlier.

Buyers outnumbered sellers: 26 funds opened new AVBP positions and 9 closed out — a net gain of 17 holders — while 25 added to existing stakes and 30 trimmed.

The largest buyer was Infinitum Asset Management, adding an estimated $28.1M. The largest seller was BlackRock, cutting an estimated $6.26M.

  • 99 institutional investors held ArriVent BioPharma (AVBP) as of Q2 2025, up from 83 in Q1 2025.
  • Funds reported $732M of ArriVent BioPharma stock for Q2 2025, up 36% quarter-over-quarter.
  • 26 funds opened new ArriVent BioPharma positions in Q2 2025 and 9 closed out, a net change of +17 holders.
  • The largest ArriVent BioPharma buyer in Q2 2025 was Infinitum Asset Management, an estimated $28.1M added.
  • The largest ArriVent BioPharma seller in Q2 2025 was BlackRock, an estimated $6.26M sold.

Based on aggregated 13F filings for Q2 2025.